BCR-ABL variants

Patent metadata

Field	Value
Publication number	US-9702877-B2
Application number	US-47231909-A
Country	US
Kind code	B2
Filing date	May 26, 2009
Priority date	Oct 31, 2008
Publication date	Jul 11, 2017
Grant date	Jul 11, 2017

Abstract

A splice variant of bcr-abl mRNA that produces BCR-ABL protein with a truncated C-terminus and its role in resistance to treatment with kinase inhibitors is disclosed. Vectors for expressing the truncated gene product are provided as well as recombinant cells that express the truncated gene product from a cDNA construct. Also provided are methods compositions and kits for detecting the BCR-ABL splice variant. Additionally, methods for screening BCR-ABL kinase domain inhibitors which rely on the recombinant cells and methods of predicting likelihood for resistance of a CML patient with a BCR/ABL translocation respond to treatment with one or more BCR-ABL kinase inhibitors are also disclosed.

First claim

What is claimed is:

1. A method for detecting a 35 INS BCR-ABL splice variant comprising SEQ ID NO:1, comprising:
(a) performing a nucleic acid amplification reaction on a bcr-abl mRNA sample, or cDNA derived therefrom with at least one primer pair, comprising:
(i) a forward primer that hybridizes to exon 8 of the abl gene and a reverse primer comprising SEQ ID NO: 23; or
(ii) a forward primer comprising SEQ ID NO: 22 that hybridizes to exon 9 of the abl gene, wherein one or both primers of the primer pair is labeled;

(b) detecting an amplification product that comprises SEQ ID NO: 1, thereby detecting the bcr-abl splice variant.

2. The method of claim 1 , further comprising detecting the presence or absence of at least one mutation in the abl portion of the bcr-abl gene.

3. The method of claim 1 , further comprising detecting said bcr-abl splice variant mRNA using probe hybridization.

4. The method of claim 1 , further comprising sequencing the amplification products.

5. The method of claim 1 , wherein the bcr-abl mRNA sample is from a human chronic myelogenous leukemia (CML) patient.

6. The method of claim 5 , wherein the human CML patient has been administered imatinib.

7. A method for detecting a 35 INS BCR-ABL splice variant comprising SEQ ID NO:1, the method comprising:
(a) performing a nucleic acid amplification reaction on a bcr-abl mRNA sample, or a bcr-abl cDNA derived therefrom, using at least a primer pair, comprising:
(i) a forward primer comprising SEQ ID NO: 5 and a reverse primer that hybridizes to exon 9 of the abl gene; or
(ii) a forward primer that hybridizes to exon 8 of the abl gene and a reverse primer that comprises SEQ ID NO: 6; and

(b) detecting an amplification product that comprises SEQ ID NO: 1, thereby detecting the bcr-abl splice variant, wherein the amplification product is detected with a labeled oligonucleotide probe, wherein the labeled oligonucleotide probe hybridizes to at least 10 contiguous nucleotides of SEQ ID NO: 4.

8. The method of claim 7 , wherein the bcr-abl mRNA sample is from a human chronic myelogenous leukemia (CML) patient.

9. The method of claim 8 , wherein the human CML patient has been administered imatinib.

10. A method for detecting a bcr-abl splice variant comprising SEQ ID NO:1, the method comprising:
(a) performing a first nucleic acid amplification reaction on a bcr-abl mRNA sample, or a bcr-abl cDNA derived therefrom, to generate a first amplification product using at least a first primer pair comprising a first forward primer that hybridizes to exon b2 of the bcr gene and a first reverse primer that hybridizes to a region at the junction of exon 9 and 10 of the abl gene;
(b) performing a second nucleic acid amplification reaction on the first amplification product to generate second amplification product using at least a second primer pair comprising a second forward primer that hybridizes to exon 8 of the abl gene and a second reverse primer that hybridizes to exon 9 of the abl gene, wherein one or both primers of the second primer pair is labeled; and
(c) detecting the second amplification product that comprises SEQ ID NO: 1, based on the size of the second amplification product, thereby detecting the bcr-abl splice variant.

11. The method of claim 10 , wherein the first forward primer forward primer comprises SEQ ID NO: 5.

12. The method of claim 10 , wherein the first reverse primer comprises SEQ ID NO: 6.

13. The method of claim 10 , wherein the second forward primer comprises SEQ ID NO: 22.

14. The method of claim 10 , wherein the second reverse primer comprises SEQ ID NO: 23.

15. The method of claim 10 , wherein the second amplification product that comprises SEQ ID NO: 1 is detected with a labeled oligonucleotide probe.

16. The method of claim 15 , wherein the labeled oligonucleotide probe hybridizes to at least 10 contiguous nucleotides of SEQ ID NO: 4.

17. The method of claim 10 , wherein the bcr-abl mRNA sample is from a human chronic myelogenous leukemia (CML) patient.

18. The method of claim 17 , wherein the human CML patient has been administered imatinib.

Assignees

• Albitar Maher
• Quest Diagnostics Invest Inc

Inventors

• Albitar Maher

Classifications

• G01N33/57505 Primary

  of the blood, e.g. leukaemia · CPC title

• A61K31/506

  not condensed and containing further heterocyclic rings · CPC title

• A61K31/497

  containing further heterocyclic rings · CPC title

• C07K14/82

  Translation products from oncogenes · CPC title

• C07K2319/00

  Fusion polypeptide · CPC title